type2 diabetes
Conditions
Interventions
Semaglutide group: In hospitalization, participants inject semaglutide 0.25mg once a week. After discharge, participants inject semaglutide 0.50mg once a week in 12 weeks.
Control group: Paticipant
Sponsors
Saiseikai Yokohamashi Nanbu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type2 diabetic inpatients 2) Patinets never receiving GLP-1 receptor agonists 3) Diabetes duration within 10 years 4) Patients with the written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with severe liver dysfunction 2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73) 3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0 4) Patinet with diabetic ketoacidosis 5) Patient with infection 6) Patients taking steroid 7) Patients with malignant tumor currently undergoing treatment 8) Pregnant or lactating woman 9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference of insulin secretory ability (such as urine CPR, serum C-peptide and CPRindex in fasting, AUC of serum C-peptide during the GST) in three months after discharge between type2 diabetic inpatients who receive semaglutide or not. | — |
Countries
Japan
Contacts
Public ContactTaichi Minami
Saiseikai Yokohamashi Nanbu Hospital Department of Diabetes and Endocrinology
Outcome results
None listed